stoxline Quote Chart Rank Option Currency Glossary
Genmab A/S (GMAB)
26.77  -0.55 (-2.01%)    06-12 16:00
Open: 27.02
High: 27.05
Volume: 565,825
Pre. Close: 27.32
Low: 26.73
Market Cap: 17,440(M)
Technical analysis
2024-06-12 4:22:26 PM
Short term     
Mid term     
Targets 6-month :  33.87 1-year :  35.51
Resists First :  29 Second :  30.4
Pivot price 28.24
Supports First :  26.72 Second :  22.23
MAs MA(5) :  27.66 MA(20) :  28.62
MA(100) :  28.89 MA(250) :  32.36
MACD MACD :  -0.5 Signal :  -0.3
%K %D K(14,3) :  7 D(3) :  10
RSI RSI(14): 35
52-week High :  42.72 Low :  26.31
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GMAB ] has closed below the lower bollinger band by 0.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ GMAB ] is to continue within current trading range. Bollinger Bands are 2.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 27.1 - 27.26 27.26 - 27.42
Low: 26.29 - 26.47 26.47 - 26.65
Close: 26.45 - 26.74 26.74 - 27.07
Company Description

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Headline News

Wed, 12 Jun 2024
Genmab Rewards Employees with Stock Incentives - - TipRanks

Wed, 12 Jun 2024
8670 Shares in Genmab A/S (NASDAQ:GMAB) Acquired by Lighthouse Investment Partners LLC - Defense World

Wed, 12 Jun 2024
Grant of Restricted Stock Units and Warrants to Employees in Genmab - Yahoo Finance UK

Wed, 12 Jun 2024
Genmab Insider Lowered Holding By 71% During Last Year - Simply Wall St

Tue, 11 Jun 2024
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely ... - GlobeNewswire

Mon, 10 Jun 2024
Genmab Advances Share Buy-back Program - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 642 (M)
Shares Float 64 (M)
Held by Insiders 0 (%)
Held by Institutions 7.5 (%)
Shares Short 2,750 (K)
Shares Short P.Month 2,630 (K)
Stock Financials
EPS 1.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 498.86
Profit Margin 30.7 %
Operating Margin 19.3 %
Return on Assets (ttm) 10.6 %
Return on Equity (ttm) 18.3 %
Qtrly Rev. Growth 45.2 %
Gross Profit (p.s.) 0
Sales Per Share 27.67
EBITDA (p.s.) 9.26
Qtrly Earnings Growth 488.2 %
Operating Cash Flow 5,660 (M)
Levered Free Cash Flow 3,830 (M)
Stock Valuations
PE Ratio 22.12
PEG Ratio 2
Price to Book value 0.05
Price to Sales 0.96
Price to Cash Flow 3.03
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android